Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 6NIH 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma 32Lymphoma, Non-Hodgkin 25Lymphoma, B-Cell 15Lymphoma, Follicular 13Recurrence 11Lymphoma, Large B-Cell, Diffuse 11Hodgkin Disease 11Leukemia 10Multiple Myeloma 9Burkitt Lymphoma 8Leukemia, Myeloid, Acute 5Neoplasms 4Lymphoma, T-Cell, Peripheral 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hematologic Neoplasms 4Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Prostatic Neoplasms 2Obesity 2Neoplasm, Residual 2Mycosis Fungoides 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2HIV Infections 2Febrile Neutropenia 2Colonic Neoplasms 2Breast Neoplasms 2

Interventions

Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Castleman Disease × Lymphoid × Clear all
NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

French National Agency for Research on AIDS and Viral Hepatitis

Phase 2 Terminated
25 enrolled
LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡